SMAD3 and type 2 diabetes mellitus: This may explain the finding that SIS3 treatment significantly blocked the intrarenal TGF-β/Smad3 signaling and T2DN with minimal effect on protection against Pax 6 loss and T2D as seen in this study in established db/db mice.